spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  neutralizing antibody 

 HSMN NewsFeed - 29 Apr 2024
Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B
Biopharmaceuticals Diagnostics FDA
 HSMN NewsFeed - 1 Jun 2022
Codagenix Receives FDA Clearance of Investigational New Drug Application for Live-Attenuated, Intranasal RSV Vaccine Candidate CodaVax(TM)-RSV
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Dec 2021
Chemomab Therapeutics Names David M. Weiner, MD as Interim Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Jul 2021
Hummingbird Bioscience and MD Anderson Announce Strategic Research Collaboration To Advance Innovative Immunotherapies
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Apr 2021
Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Feb 2021
Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19
Biopharmaceuticals
 HSMN NewsFeed - 28 Oct 2020
Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19
Biopharmaceuticals
 HSMN NewsFeed - 7 Oct 2020
Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs
Biopharmaceuticals
 HSMN NewsFeed - 3 Aug 2020
Lilly Initiates Phase 3 Trial of LY-CoV555 for Prevention of COVID-19 at Long-Term Care Facilities in Partnership with the National Institute of Allergy and Infectious Diseases (NIAID)
Biopharmaceuticals
 HSMN NewsFeed - 8 Jun 2020
Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment
Biopharmaceuticals
 HSMN NewsFeed - 13 Jul 2016
Lilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 May 2008
CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date
Biopharmaceuticals
 HSMN NewsFeed - 10 Dec 2007
Pivotal Phase 3 NPLATE(TM) Study in Non-Splenectomized Patients Met Primary Endpoints
Biopharmaceuticals
 HSMN NewsFeed - 11 Apr 2007
First Pharmacoeconomic Analysis with Long-Term Data Showed COPAXONE(R) Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Sep 2006
One-year Data From Phase III Trial Show That New Formulation of Rebif(r) Offers Substantial Improvement in Tolerability and Immunogenicity Profiles
Biopharmaceuticals Neurology
Return to NewsFeed  

 Additional items found! 6

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 6 additional stories matching:
neutralizing antibody
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!